San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Aethlon Medical is raising $2,733,797.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, James Frakes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aethlon Medical

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

To learn more about Aethlon Medical, visit http://www.aethlonmedical.com/

Contact:
James Frakes, Chief Financial Officer
858-459-7800
jfrakes@aethlonmedical.com
https://www.linkedin.com/in/jim-frakes-40b02b12/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved